Could cfDNA Revolutionize Gallbladder Cancer Diagnosis?
A pilot study published in JHEP Reports (Daniels M et al., 2026) suggests that analysing circulating cell‑free DNA (cfDNA) fragmentomics in blood can help distinguish gallbladder cancer (GBC) from benign gallbladder disease and healthy individuals. Using archived plasma from 67 participants enrolled in two case–control studies in China and Chile, researchers applied low‑coverage whole‑genome sequencing and computational analyses to search for cancer‑specific cfDNA signatures and built a classification model that separated GBC from non‑cancer groups with an area under the curve (AUC) of 0.852.
Gallbladder cancer is uncommon but highly lethal, frequently diagnosed at an advanced stage because symptoms are vague and current non‑invasive tests are unreliable. Common serum markers such as carbohydrate antigen 19‑9 (CA19‑9) and carcinoembryonic antigen (CEA) lack the sensitivity required for diagnosis, and imaging often cannot reliably distinguish benign from malignant disease-especially when chronic inflammation or other gallbladder conditions are present. Globally, gallstones affect roughly 10–20% of adults and up to 30–40% in some South American regions (including Chile); although gallstones are found in over 90% of GBC cases in high‑risk areas, fewer than 1% of people with gallstones develop cancer. Five‑year survival for GBC remains low, around 19%.
In the study, patients with GBC showed statistically significant differences (p<0.05) in multiple fragmentomics features compared with healthy controls and people with gallstones: cfDNA fragment length distributions, end‑motif patterns, estimated tumour fraction, detectable copy‑number alterations and accessibility at transcription factor binding sites. Many of these cfDNA alterations matched patterns seen in tissue genomics and in related hepatopancreatobiliary cancers, supporting the biological relevance of the findings. The investigators also reported that archived plasma could be successfully profiled for cfDNA, which could broaden opportunities for retrospective biomarker research. The authors characterise the work as proof of concept rather than definitive clinical evidence. If validated in larger, prospective cohorts, cfDNA fragmentomics could become a non‑invasive adjunct to imaging and serum testing-helping risk stratification, informing clinical decisions and potentially prioritising cholecystectomy waitlists in high‑risk populations. Further validation and clinical studies are needed before routine use. Original Source: https://www.emjreviews.com/hepatology/news/gallbladder-cancer-diagnosis-shows-promise-with-cfdna-fragmentomics/ Category: Tags: Publish Date: 2026-07-31 14:35:00